These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

766 related items for PubMed ID: 10077233

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
    Kreutz RP, Nystrom P, Kreutz Y, Miao J, Kovacs R, Desta Z, Flockhart DA, Jin Y.
    Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
    [Abstract] [Full Text] [Related]

  • 7. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM, Savi P.
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [Abstract] [Full Text] [Related]

  • 8. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H.
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [Abstract] [Full Text] [Related]

  • 9. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH.
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [Abstract] [Full Text] [Related]

  • 10. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F.
    J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
    [Abstract] [Full Text] [Related]

  • 11. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V.
    Thromb Res; 2007 Jul; 119(3):277-84. PubMed ID: 16563469
    [Abstract] [Full Text] [Related]

  • 12. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
    Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP.
    Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604
    [Abstract] [Full Text] [Related]

  • 13. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate.
    Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannucci PM.
    Thromb Haemost; 1991 Dec 02; 66(6):694-9. PubMed ID: 1665598
    [Abstract] [Full Text] [Related]

  • 14. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.
    Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP.
    Biochem Pharmacol; 1990 Dec 15; 40(12):2683-7. PubMed ID: 2175608
    [Abstract] [Full Text] [Related]

  • 15. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA, Bliden KP, Etherington A, Tantry US.
    Thromb Res; 2007 Dec 15; 121(1):107-15. PubMed ID: 17400283
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK.
    Platelets; 2003 Dec 15; 14(7-8):421-7. PubMed ID: 14713511
    [Abstract] [Full Text] [Related]

  • 17. Identification and biological activity of the active metabolite of clopidogrel.
    Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM.
    Thromb Haemost; 2000 Nov 15; 84(5):891-6. PubMed ID: 11127873
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of rat platelet aggregation by mycalolide-B, a novel inhibitor of actin polymerization with a different mechanism of action from cytochalasin-D.
    Sugidachi A, Ogawa T, Asai F, Saito S, Ozaki H, Fusetani N, Karaki H, Koike H.
    Thromb Haemost; 1998 Mar 15; 79(3):614-9. PubMed ID: 9531051
    [Abstract] [Full Text] [Related]

  • 19. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
    Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H.
    Br J Pharmacol; 2001 Jan 15; 132(1):47-54. PubMed ID: 11156560
    [Abstract] [Full Text] [Related]

  • 20. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H, Andre P, Mills S, Phillips DR, Conley PB.
    J Pharmacol Exp Ther; 2011 Oct 15; 339(1):54-61. PubMed ID: 21730013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.